medwireNews: The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending that three multikinase inhibitor agents be made available for patients with thyroid cancer.
Cabozantinib should now be a routinely available option for National Health Service patients with inoperable, locally advanced, or metastatic medullary thyroid cancer, states the final appraisal determination for the agent.
In addition, the multikinase inhibitors lenvatinib and sorafenib have both been recommended for the treatment of patients with locally advanced or metastatic differentiated thyroid cancers that have continued to progress despite surgery and radioactive iodine therapy.
Use of both of these drugs, however, is dependent, on the discount agreed with their manufacturers, the final appraisal determinations state.
Of note, the technology appraisal for the multikinase inhibitor vandetanib and its associated recommendations for thyroid cancer will be released at a later date.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group